Second Line Breast Cancer Trial

Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors

NCT00253422 ·Status: COMPLETED ·Phase: PHASE3

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

NCT00065325 ·Status: COMPLETED ·Phase: PHASE3

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

NCT00099437 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)

NCT00944918 ·Status: COMPLETED ·Phase: PHASE3

Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer

NCT00201864 ·Status: COMPLETED ·Phase: PHASE2

Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole

NCT00543127 ·Status: TERMINATED ·Phase: PHASE3

Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer

NCT00357110 ·Status: COMPLETED ·Phase: PHASE2

Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer

NCT00206414 ·Status: TERMINATED ·Phase: PHASE2

Faslodex 500mg Multiple Dose Tolerability Study in BC Patients

NCT00328120 ·Status: COMPLETED ·Phase: PHASE1

Quality Of Life While Receiving Faslodex

NCT00643513 ·Status: COMPLETED

Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France

NCT00681369 ·Status: COMPLETED

Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.

NCT00287534 ·Status: COMPLETED ·Phase: PHASE2

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

NCT00057941 ·Status: COMPLETED ·Phase: PHASE2

Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer

NCT00562458 ·Status: COMPLETED

Efficacy and Safety of 500mg of Fulvestrant

NCT00585507 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years

NCT00286117 ·Status: COMPLETED ·Phase: PHASE3

Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women

NCT00186121 ·Status: COMPLETED ·Phase: PHASE2

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers

NCT06995482 ·Status: RECRUITING ·Phase: PHASE1

Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC

NCT02140437 ·Status: WITHDRAWN ·Phase: PHASE2

Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer

NCT00871858 ·Status: COMPLETED ·Phase: PHASE2

Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy

NCT00256698 ·Status: COMPLETED ·Phase: PHASE3

Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer

NCT00049062 ·Status: COMPLETED ·Phase: PHASE2

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

NCT00754325 ·Status: COMPLETED ·Phase: PHASE2

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

NCT01151215 ·Status: TERMINATED ·Phase: PHASE2

ATAC - Pharmacokinetics (PK) Sub-Protocol

NCT00784862 ·Status: COMPLETED ·Phase: PHASE3